Clintrex Research Corporation, Sarasota, Florida, USA.
Center for Health & Technology, University of Rochester, Rochester, New York, USA.
Mov Disord. 2021 Jan;36(1):59-63. doi: 10.1002/mds.28310. Epub 2020 Oct 7.
A disease-modifying therapy that slows disease progression and development of disability is the major unmet need in the treatment of Parkinson's disease. Recent scientific advances suggest many promising and exciting new interventions. However, despite these opportunities, the cost, time and uncertainty of being able to receive an indication as a disease-modifying therapy has caused many pharmaceutical companies to abandon development of potentially disease-modifying drugs. We propose a new approach to development of these agents that will reduce the cost and facilitate approval of putative disease-modifying drugs that should prove acceptable to pharmaceutical companies and regulatory agencies. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
一种能够减缓疾病进展和残疾发展的疾病修正疗法是帕金森病治疗中尚未满足的主要需求。最近的科学进步表明了许多有前途和令人兴奋的新干预措施。然而，尽管有这些机会，但由于作为疾病修正疗法获得批准的成本、时间和不确定性，许多制药公司已经放弃了潜在疾病修正药物的开发。我们提出了一种新的方法来开发这些药物，这将降低成本，并促进潜在的疾病修正药物的批准，这应该能让制药公司和监管机构接受。 © 2020 作者。运动障碍由 Wiley 期刊有限责任公司代表国际帕金森病和运动障碍协会出版。
